Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Warner-Lambert profiles ACAT inhibitors with hypocholesterolemic and antiatherosclerotic activity

Sep. 13, 1996

Site-specific catalytic cleavage of RNA achieved with ribozyme analogue

Sep. 13, 1996

Dolastatin 10 mimic dolaphenine androstane

Sep. 13, 1996

Antiangiogenic eponemycin analogues

Sep. 13, 1996

Dual TNF production and PDE IV inhibitor from Pfizer

Sep. 13, 1996

A new class of selective COX-2 inhibitors from Merck Frosst

Sep. 13, 1996

Antirhinovirus compounds from Lilly

Sep. 13, 1996

Antibacterial 2-pyridones, a novel class of DNA gyrase inhibitors

Sep. 13, 1996

Moxisylyte to treat erectile dysfunction

Sep. 6, 1996

Safe and effective treatment of erectile dysfunction with sildenafil

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...